Comments
Loading...
NovoCure Analyst Ratings and Price Targets | NASDAQ:NVCR | Benzinga
NovoCure Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for NovoCure Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
HC Wainwright & Co.
Piper Sandler
Evercore ISI Group
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for NovoCure
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/10/2025 | Buy Now | — | JP Morgan | Jessica Fye65% | $29 → $28 | Maintains | Neutral | Get Alert |
| 01/14/2025 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | — | Piper Sandler | Jason Bednar52% | $28 → $42 | Maintains | Overweight | Get Alert |
| 12/03/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $30 → $38 | Maintains | Buy | Get Alert |
| 12/02/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $30 → $38 | Reiterates | Buy → Buy | Get Alert |
| 12/02/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar50% | $18 → $30 | Upgrade | In-Line → Outperform | Get Alert |
| 11/21/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $24 → $30 | Upgrade | Neutral → Buy | Get Alert |
| 10/01/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar50% | $21 → $18 | Maintains | In-Line | Get Alert |
| 07/26/2024 | Buy Now | — | Wells Fargo | Larry Biegelsen67% | $42 → $40 | Maintains | Overweight | Get Alert |
| 07/26/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $22 → $24 | Maintains | Neutral | Get Alert |
| 07/02/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar50% | $14.5 → $20 | Maintains | In-Line | Get Alert |
| 06/04/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 05/02/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $24 → $22 | Maintains | Neutral | Get Alert |
| 04/10/2024 | Buy Now | — | Piper Sandler | Jason Bednar52% | $25 → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | Buy Now | — | Wells Fargo | Larry Biegelsen67% | $49 → $42 | Maintains | Overweight | Get Alert |
| 03/27/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $22 → $24 | Maintains | Neutral | Get Alert |
| 03/19/2024 | Buy Now | — | JP Morgan | Jessica Fye65% | $15 → $17 | Maintains | Neutral | Get Alert |
| 03/12/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 02/23/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar50% | $14 → $15 | Maintains | In-Line | Get Alert |
| 02/22/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $21 → $22 | Maintains | Buy | Get Alert |
| 08/29/2023 | Buy Now | — | Wells Fargo | Larry Biegelsen67% | $102 → $49 | Maintains | Overweight | Get Alert |
| 08/28/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | → $25 | Downgrade | Buy → Neutral | Get Alert |
| 08/08/2023 | Buy Now | — | Piper Sandler | Jason Bednar52% | → $45 | Upgrade | Neutral → Overweight | Get Alert |
| 08/04/2023 | Buy Now | — | SVB Leerink | Jonathan Chang39% | → $51 | Initiates | → Outperform | Get Alert |
| 07/31/2023 | Buy Now | — | Evercore ISI Group | Vijay Kumar50% | → $33 | Upgrade | Underperform → In-Line | Get Alert |
| 07/28/2023 | Buy Now | — | Wells Fargo | Larry Biegelsen67% | $104 → $102 | Maintains | Overweight | Get Alert |
| 07/27/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | → $85 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | Buy Now | — | Piper Sandler | Jason Bednar52% | $67 → $62 | Maintains | Neutral | Get Alert |
| 06/07/2023 | Buy Now | — | Wedbush | David Nierengarten60% | $53 → $46 | Upgrade | Underperform → Neutral | Get Alert |
| 06/06/2023 | Buy Now | — | Truist Securities | Gregory Fraser64% | → $95 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | → $115 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | — | Wells Fargo | Larry Biegelsen67% | $70 → $104 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/05/2023 | Buy Now | — | Truist Securities | Gregory Lewis68% | $102 → $95 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $130 → $115 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | — | JP Morgan | Jessica Fye65% | $99 → $50 | Downgrade | Neutral → Underweight | Get Alert |
| 01/17/2023 | Buy Now | — | Piper Sandler | Jason Bednar52% | $70 → $80 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | — | JP Morgan | Jessica Fye65% | $86 → $99 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | — | Wells Fargo | Larry Biegelsen67% | $89 → $107 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/29/2022 | Buy Now | — | Wells Fargo | Larry Biegelsen67% | $74 → $89 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/28/2022 | Buy Now | — | Truist Securities | Gregory Fraser64% | $105 → $102 | Maintains | Buy | Get Alert |
| 10/28/2022 | Buy Now | — | Wells Fargo | Larry Biegelsen67% | $70 → $74 | Maintains | Equal-Weight | Get Alert |
| 10/28/2022 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | $115 → $100 | Maintains | Buy | Get Alert |
| 10/24/2022 | Buy Now | — | Piper Sandler | Jason Bednar52% | $90 → $70 | Downgrade | Overweight → Neutral | Get Alert |
| 07/29/2022 | Buy Now | — | Truist Securities | Gregory Fraser64% | $118 → $105 | Maintains | Buy | Get Alert |
| 07/05/2022 | Buy Now | — | Evercore ISI Group | Vijay Kumar50% | — | Downgrade | In-Line → Underperform | Get Alert |
| 05/16/2022 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar36% | → $115 | Initiates | → Buy | Get Alert |
| 05/13/2022 | Buy Now | — | Piper Sandler | Jason Bednar52% | $125 → $100 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for NovoCure (NVCR) stock?
The latest price target for NovoCure (NASDAQ:NVCR) was reported by JP Morgan on April 10, 2025. The analyst firm set a price target for $28.00 expecting NVCR to rise to within 12 months (a possible 72.73% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NovoCure (NVCR)?
The latest analyst rating for NovoCure (NASDAQ:NVCR) was provided by JP Morgan, and NovoCure maintained their neutral rating.
When was the last upgrade for NovoCure (NVCR)?
The last upgrade for NovoCure Ltd happened on December 2, 2024 when Evercore ISI Group raised their price target to $30. Evercore ISI Group previously had an in-line for NovoCure Ltd.
When was the last downgrade for NovoCure (NVCR)?
The last downgrade for NovoCure Ltd happened on August 28, 2023 when HC Wainwright & Co. changed their price target from N/A to $25 for NovoCure Ltd.
When is the next analyst rating going to be posted or updated for NovoCure (NVCR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NovoCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NovoCure was filed on April 10, 2025 so you should expect the next rating to be made available sometime around April 10, 2026.
Is the Analyst Rating NovoCure (NVCR) correct?
While ratings are subjective and will change, the latest NovoCure (NVCR) rating was a maintained with a price target of $29.00 to $28.00. The current price NovoCure (NVCR) is trading at is $16.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.